Hepron Molecular Lab, Inc. is a privately owned, early stage biotechnology company developing fast, accurate, and cutting edge DNA based diagnostic technology for the detection of Hepatitis B Virus (HBV) and its related diseases such as HBV-related cirrhosis and liver cancer. The firm's current effort organizes around development a quantitative cccDNA assay in serum based on Hepron's proprietary technology. Quantitative detection of HBV cccDNA is highly desirable in both academic and medical industries for anti-HBV drug development and also for patient care.
